使用标记89Zr或211At的抗磷脂酰肌醇蛋白聚糖-1抗体进行免疫PET和靶向α治疗:胰腺导管腺癌的诊疗一体化方法
本研究评估了标记89Zr或211At的抗磷脂酰肌醇蛋白聚糖-1(GPC1)单克隆抗体在胰腺导管腺癌诊疗中的潜力。PANC-1荷瘤小鼠给予[89Zr]GPC1后早期肿瘤摄取高(SUVmax 3.85±0.10),[211At]GPC1可抑制肿瘤生长,GPC1是胰腺导管腺癌精准诊断和靶向诊疗一体化的有前景靶点。
要点
- [89Zr]GPC1 mAb在给药后早期即显示高肿瘤摄取,SUVmax为3.85±0.10。
- [211At]GPC1 mAb在PANC-1荷瘤小鼠中观察到肿瘤生长抑制。
- 内化抑制剂可显著抑制[211At]GPC1 mAb的抗肿瘤效果,提示内化能力的重要作用。
核心结论
- [89Zr]GPC1 mAb PET在给药后早期显示高肿瘤摄取,使用[211At]GPC1 mAb的靶向α治疗显示肿瘤生长抑制,GPC1是胰腺导管腺癌精准诊断和靶向诊疗一体化的有前景靶点。
研究设计与样本
- 研究将抗GPC1单克隆抗体克隆01a033分别通过去铁胺或十硼烷链接剂标记89Zr或211At,用共聚焦显微镜评估荧光偶联抗体的内化能力,PANC-1异种移植小鼠(n=6)静脉给予[89Zr]GPC1 mAb(0.91±0.10 MBq)后行7天PET/CT扫描,并用GPC1阳性(BxPC-3)与GPC1阴性(BxPC-3 GPC1敲除)异种移植(各n=3)及阻断研究确认摄取特异性,用γH2AX抗体评估DNA双链断裂,PANC-1异种移植小鼠(n=10)给予[211At]GPC1 mAb(约100 kBq)评估抗肿瘤效果。
主要发现
- GPC1 mAb克隆01a033的内化比率随时间增加;给药后1天PANC-1异种移植中[89Zr]GPC1 mAb高蓄积(SUVmax 3.85±0.10),至第7天逐渐降至SUVmax 2.16±0.30;BxPC-3异种移植摄取显著高于BxPC-3 GPC1敲除异种移植(SUVmax分别为4.66±0.40和2.36±0.36,P=0.05);阻断组摄取较非阻断组显著抑制(每克注射剂量百分比分别为7.3±1.3和12.4±3.0,P=0.05);加入150 kBq [211At]GPC1后观察到DNA双链断裂,内化抑制剂(dynasore)显著抑制该断裂;PANC-1小鼠给予[211At]GPC1 mAb后观察到肿瘤生长抑制,内化抑制剂(丙氯拉嗪)显著抑制[211At]GPC1 mAb的治疗效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glypican-1 (GPC1) is overexpressed in several solid cancers and is associated with tumor progression, whereas its expression is low in normal tissues. This study aimed to evaluate the potential of an anti-GPC1 monoclonal antibody (GPC1 mAb) labeled with 89Zr or 211At as a theranostic target in pancreatic ductal adenocarcinoma. Methods: GPC1 mAb clone 01a033 was labeled with 89Zr or 211At with a deferoxamine or decaborane linker, respectively. The internalization ability of GPC1 mAb was evaluated by fluorescence conjugation using a confocal microscope. PANC-1 xenograft mice (n = 6) were intravenously administered [89Zr]GPC1 mAb (0.91 ± 0.10 MBq), and PET/CT scanning was performed for 7 d. Uptake specificity was confirmed through a comparative study using GPC1-positive (BxPC-3) and GPC1-negative (BxPC-3 GPC1-knockout) xenografts (each n = 3) and a blocking study. DNA double-strand breaks were evaluated using the γH2AX antibody. The antitumor effect was evaluated by administering [211At]GPC1 mAb (∼100 kBq) to PANC-1 xenograft mice (n = 10). Results: GPC1 mAb clone 01a033 showed increased internalization ratios over time. One day after administration, a high accumulation of [89Zr]GPC1 mAb was observed in the PANC-1 xenograft (SUVmax, 3.85 ± 0.10), which gradually decreased until day 7 (SUVmax, 2.16 ± 0.30). The uptake in the BxPC-3 xenograft was significantly higher than in the BxPC-3 GPC1-knockout xenograft (SUVmax, 4.66 ± 0.40 and 2.36 ± 0.36, respectively; P = 0.05). The uptake was significantly inhibited in the blocking group compared with the nonblocking group (percentage injected dose per gram, 7.3 ± 1.3 and 12.4 ± 3.0, respectively; P = 0.05). DNA double-strand breaks were observed by adding 150 kBq of [211At]GPC1 and were significantly suppressed by the internalization inhibitor (dynasore), suggesting a substantial contribution of the internalization ability to the antitumor effect. Tumor growth suppression was observed in PANC-1 mice after the administration of [211At]GPC1 mAb. Internalization inhibitors (prochlorperazine) significantly inhibited the therapeutic effect of [211At]GPC1 mAb, suggesting an essential role in targeted α-therapy. Conclusion: [89Zr]GPC1 mAb PET showed high tumoral uptake in the early phase after administration, and targeted α-therapy using [211At]GPC1 mAb showed tumor growth suppression. GPC1 is a promising target for future applications for the precise diagnosis of pancreatic ductal adenocarcinoma and GPC1-targeted theranostics.
引用
- Watabe T, Kabayama K, Naka S, et al. Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma. J Nucl Med. 2023. PMID: 37827841. doi:10.2967/jnumed.123.266313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。